Skip to main content

""

Ongoing Private
Sector Projects

The following projects are currently being completed by DAS. Projects are listed in the order in which Research Ethics Board approval was obtained.

Client: IQVIA Solutions Canada Inc.

Project ID: P2018-040/2020 0970 173 000

Research Question/Objectives: In December 2015, mepolizumab, was approved in Canada as add-on maintenance for the treatment of adult patients with uncontrolled eosinophilic severe asthma. Despite compelling clinical trial evidence, many stakeholders still seek to better understand if the value seen in randomized studies is realized in actual clinical practice. Now, with over two years of real-world data available, this study would like to investigate the real-world impact of mepolizumab on asthma related clinical outcomes, healthcare resource use and costs among severe asthma patients, outside of the randomized clinical trial setting. The objective of the current research project primarily is to estimate the demographic and cliccal characteristics of real-world mepolizumab patients. The project team is also interested in comparison of asthma related real-world outcomes of post-mepolizumab initiation versus pre-mepolizumab initiation.

Research objectives

Primary Objectives:

  • Describe the demographic and clinical characteristics of real-world mepolizumab patients to understand the population with mepolizumab utilization.
  • Compare asthma-related real-world outcomes (listed below) for mepolizumab patients (post-mepolizumab initiation) versus pre-mepolizumab initiation among the same patients to determine the effectiveness of mepolizumab in actual clinical practice.
  • Compare costs associated with asthma-related real-world outcomes for mepolizumab patients (post-mepolizumab initiation) versus pre-mepolizumab initiation among same patients to evaluate the differences from the public payer’s perspective.

Secondary Objective:

  • Investigate the real-world asthma-related outcomes and associated costs (as listed above under primary objectives) for highly adherent (≥ 9 injections) mepolizumab patients (i.e. sub cohort) post versus premepolizumab initiation to understand the impact of mepolizumab among patients who are highly adherent.

Availability of Results: study in progress


Client: AstraZeneca Canada/Broadstreet Health Economics

Project ID: P2020-069/2021 0970 226 000

Research Question/Objectives: The overall aim is to understand the impact of chronic obstructive pulmonary disease (COPD) exacerbations and the pattern of treatment to characterize disease trajectory and burden of disease among COPD patients in Canada, over time, from diagnosis to death, and how this may differ by treatment patterns. To characterize the frequency and time to exacerbations and other acute and chronic comorbidities, as well as health care resource uses, over a patient's lifetime, in relation to their treatment.

Specifically, the research objectives of interest are:

  • Characterize the health and treatment trajectories of patients with COPD from diagnosis to death.
  • Assess clinical outcomes and health care resource use following moderate to severe COPD exacerbations (in the first year of follow-up), combined and stratified by severity of exacerbation (mild vs. severe).
  • Characterize the health and treatment trajectories of patients with COPD between and within each treatment-bound time period (i.e. while on mono-, dual-, or triple-therapy).
  • Describe the treatment patterns and burden of disease by different treatment groups at baseline (first year of follow-up).
  • Describe burden of disease in different treatment groups, by treatment at baseline.
  • Assess the impact of different treatment algorithms on patient, specifically on time to exacerbations and survival.
  • Describe the association of early vs delayed treatment after COPD diagnosis with Fixed-Dose Combination (FDC) Triple and resource utilization/cost-saving.
  • Describe the association of specific co-morbidities and exacerbations.
  • Explore association of biomarkers with exacerbation risk, if available.

Availability of Results: study in progress

Client: Astellas/University of Toronto

Project ID: P2020-081/2022 0970 258 000

Research Question/Objectives: What was the treatment pattern in men ≥ 66 years of age treated for lower urinary tract symptoms (LUTS) who received a prescription for overactive bladder (OAB)-specific medication or benign prostatic enlargement (BPE)-specific medication between 2009-2018, in Canada?

The specific objectives separately for OAB group and BPE group include:

  • Describe initial and subsequent management of LUTS.
  • Identify factors associated with change from initial therapy.
  • Characterize patient demographics and comorbidities.
  • Characterize healthcare utilization and healthcare-related costs and compare to a propensity score-matched cohort.
  • For OAB group, compare time to change in therapy for men who began OAB medication prior to May 28, 2015 (public insurance plan listing date for mirabegron), with those who began OAB medication on/after May 28, 2015, overall and by medication subgroups (β3-agonist vs. antimuscarinic).

Availability of Results: study in progress

Client: Sunnybrook Research Institute/HOPE Research Centre

Project ID: P2020-078/2022 0970 259 000

Research Question/Objectives: The client is looking for Canadian specific costs of various resources associated with three types of cancers for a model that requires cost, outcomes, and patient inputs.

Cost, outcomes, and patient inputs and utilization rates of various resources will be identified for the following cohorts of cancers:

  • Breast cancer
  • Metastatic non-small cell lung cancer
  • Mantle cell lymphoma.

Availability of Results: study in progress

Client: IQVIA Solutions Canada Inc.

Project ID: P2020-074/2021 0970 236 000; P2021-091/2022 0970 236 001

Research Question/Objectives: Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) are subtypes of Non-Hodgkin’s lymphoma which is cancer of the lymphatic system, it is important to know the current burden of illness of FL/MZL in Canada because it ranks as the fifth most common cancer among men and fourth most common cancer among women in Canada . However, currently available data related to the burden of illness for Canadian FL/MZL patients are limited, making it difficult to accurately assess the impact of this patient population on the health care system. The proposed study also aims to summarize characteristics of the FL/MZL patient population.

Specifically, the primary research objectives of interest are:

  • Identify FL/MZL patients and subgroups within the administrative data.
  • Describe the characteristics of FL/MZL patients and subgroups in Ontario, including:
    • incidence
    • prevalence
    • demographic characteristics
    • treatment patterns of attending physician visits, procedures, and medication use
    • health care resource utilization (HCRU) and associated direct costs; and
    • overall survival.
  • To examine the health care resource utilization (HCRU) and direct healthcare costs (i.e., BOI) for relapsed FL/MZL patients in the relapsed setting

The secondary research objectives of interest are:

  1. To describe the demographic and clinical characteristics of relapsed FL/MZL patients.
  2. To determine the first line of therapy (LoT), second LoT for relapsed FL/MZL patients.
  3. To compare HCRU and direct healthcare costs of relapsed FL/MZL patients to general population controls.
  4. To determine third LoT and time to third LoT (i.e. time to next treatment (TTNT)) for relapsed FL/MZL patients.
  5. To estimate the overall survival of relapsed FL/MZL patients.
  6. To stratify HCRU, direct healthcare costs, TTNT (third LoT), overall survival outcomes by 1st and 2nd LoT sequences.

Availability of Results: In progress


Client: IQVIA Solutions Canada Inc.

Project ID: P2020-076/2022 0970 263 000

Research Question/Objectives: Patients with rare diseases experience significant diagnostic delays and misdiagnoses, which results in several years of mistreatment and/or lack of appropriate disease management. The primary objective is to determine which diagnostic algorithms, developed in consultation with key physicians, would best predict patients who may have Fabry Disease and LOPD. Prior to testing algorithms, a cohort of Fabry Disease and LOPD patients will be created as a reference. Patients' entire histories (e.g. diagnostic codes, procedure codes, laboratory values) from 2002 to present will be used to assess whether they meet the criteria for Fabry Disease and/or LOPD for both the reference cohort and the diagnostic algorithms.

The specific aims are to:

  • Use diagnostic and procedure codes to create a Gold Standard cohort of patients with Fabry Disease and LOPD in administrative databases.
  • Compare various algorithms for Fabry Disease and LOPD to identify the most appropriate algorithm for potential use in an EMR setting.

Availability of Results: In progress


Client: IQVIA Solutions Canada Inc.

Project ID: P2020-083/2022 0970 264 000

Research Question/Objectives: Glaucoma is a family of diseases characterized by the loss of retinal ganglion cells and their nerve fibers leading to progressive, irreversible loss of visual function. It is the second leading cause of severe visual impairment and blindness worldwide Primary open-angle glaucoma is the most common form of glaucoma and was estimated to affect 44.11 million people aged 40-80 years worldwide in 2013. The study aims to describe real-world patient characteristics, treatment patterns, and outcomes in patients newly diagnosed with OAG in Canada, overall and by patient subgroups.

The specific aims are to:

  • Describe baseline patient demographic and clinical characteristics, including comorbidities (ocular and non-ocular).
  • Evaluate treatment patterns of topical glaucoma medications and rate of glaucoma-related surgeries/procedures.
  • Estimate direct healthcare resource utilization (HCRU).

Availability of Results: In progress


Client: IQVIA Solutions Canada Inc.

Project ID: P2021-092/2022 0970 266 000

Research Question/Objectives: MCL is generally considered incurable, and a relapse is almost universal. With the recent and imminent emergence of novel therapies for MCL (such as immune and targeted therapies), understanding the MCL patient profile, real-world treatment patterns, burden of illness (BOI), and outcomes among patients with newly diagnosed MCL in Canada is essential to inform decision making, especially in the context of aging population. To address this need, a retrospective, real-world study will be conducted for elderly MCL patients with a focus on those in the first-line (1L) setting.

Primary objective:

  • Describe the real-world BOI and key clinical outcomes for newly diagnosed MCL patients aged ≥65 at diagnosis.

Secondary objectives:

  • Describe the overall survival (OS) and time to next treatment (TTNT) for newly diagnosed MCL ≥65 patients in the 1st LoT with systemic therapies.
  • Determine and characterize drug treatment patterns for newly diagnosed MCL ≥65 patients in the 1st LoT with systemic therapies.
  • Compare HCRU and direct healthcare costs of newly diagnosed MCL ≥65 patients in the 1st LOT of systemic therapy to controls.
  • Describe the incidence and prevalence of newly diagnosed MCL ≥65 population

Availability of Results: In progress


Client: Charles River Associates

Project ID: P2020-077 / 2022 0970 271 000

Research Question/Objectives: Pulmonary arterial hypertension (PAH) is a rare disease with a limited understanding of the current epidemiology in Canada. PAH is associated with an elevated mortality risk, especially if left untreated. Our client has a product in development for the treatment of PAH with an expected commercial launch in the Canadian market in the near future. By improving the understanding of the treated natural history, PAH can be treated earlier and more efficiently, improving the overall survival rate of affected patients in Ontario.

The specific research objectives are:

  • What is the estimated prevalence of PAH in Ontario?
  • What is the patient profile of patients with PAH?
  • How are patients currently being treated for PAH?
  • Which specialty types are treating PAH patients and in what setting?
  • What is the health resource utilization for PAH patients?

Availability of Results: In progress




×